What changed from existing technology?
This study tested a new treatment for advanced esophageal cancer by combining a drug called tislelizumab with chemotherapy, showing better survival rates compared to chemotherapy alone.
This is the first study to show long-term survival benefits of tislelizumab combined with chemotherapy for advanced esophageal squamous cell carcinoma, with 3-year follow-up data demonstrating sustained improvement in overall survival.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
oma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306). RATIONALE-306 previously demonstrated improved overall survival (OS) in
Title ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
Tislelizumab in combination with chemotherapy may be considered as a first-line treatment option for patients with advanced/metastatic esophageal squamous cell carcinoma based on the long-term survival benefits observed in this trial.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.